STOCK TITAN

Avalo Therapeutics (AVTX) CEO exercises RSUs, shares withheld for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. Chief Executive Officer Neil Garry Arthur exercised restricted stock units that converted into common stock and had shares withheld for taxes. He exercised 64,866 restricted stock units into 64,866 shares of common stock at a conversion price of $0.00 per share. To satisfy tax obligations, 21,892 shares of common stock were disposed of at $13.89 per share through tax withholding, rather than an open-market sale. Following these transactions, he directly owns 90,114 shares of common stock. The restricted stock units stem from a 194,600-unit grant made on August 13, 2024, vesting in three equal installments on March 28, 2025, 2026, and 2027, subject to continued service.

Positive

  • None.

Negative

  • None.
Insider NEIL GARRY ARTHUR
Role Chief Executive Officer
Type Security Shares Price Value
Exercise Restricted Stock Units 64,866 $0.00 --
Exercise Common Stock 64,866 $0.00 --
Tax Withholding Common Stock 21,892 $13.89 $304K
Holdings After Transaction: Restricted Stock Units — 64,867 shares (Direct); Common Stock — 112,006 shares (Direct)
Footnotes (1)
  1. Restricted stock units convert into common stock on a one-for-one basis. On August 13, 2024, the Reporting Person was granted 194,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date.
RSUs exercised 64,866 units/shares Restricted stock units converted into common stock on March 28, 2026
Tax-withheld shares 21,892 shares at $13.89 Shares disposed to satisfy tax liability on March 28, 2026
Post-transaction holdings 90,114 shares Common stock directly owned by CEO after transactions
Original RSU grant 194,600 units Grant dated August 13, 2024, vesting in three annual tranches
First vesting tranche 64,866 units One-third of 194,600-unit RSU grant vesting on March 28, 2025
Restricted stock units financial
"Restricted stock units convert into common stock on a one-for-one basis."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax-withholding disposition financial
"Payment of exercise price or tax liability by delivering securities"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vesting financial
"vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
NEIL GARRY ARTHUR

(Last)(First)(Middle)
C/O AVALO THERAPEUTICS, INC.
1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)
WAYNE PENNSYLVANIA 19087

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/28/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock03/28/2026M64,866A(1)112,006D
Common Stock03/28/2026F21,892D$13.8990,114D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)03/28/2026M64,866 (2) (2)Common Stock64,866$064,867D
Explanation of Responses:
1. Restricted stock units convert into common stock on a one-for-one basis.
2. On August 13, 2024, the Reporting Person was granted 194,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date.
/s/ Christopher Sullivan, Attorney-in-Fact03/31/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Avalo Therapeutics (AVTX) report for its CEO?

Avalo Therapeutics reported that CEO Neil Garry Arthur exercised 64,866 restricted stock units into common shares, with 21,892 shares withheld to cover taxes. These actions are compensation-related and reflect vesting of previously granted equity rather than an open-market share purchase or sale.

How many Avalo Therapeutics (AVTX) shares does the CEO hold after this Form 4?

After the reported transactions, CEO Neil Garry Arthur directly holds 90,114 shares of Avalo Therapeutics common stock. This figure reflects the net position after exercising 64,866 restricted stock units and having 21,892 shares withheld to satisfy tax obligations associated with the vesting event.

What happened to the 21,892 Avalo Therapeutics (AVTX) shares shown as disposed?

The 21,892 Avalo Therapeutics shares labeled with code F were withheld to pay tax liabilities from the vesting and exercise of restricted stock units. This tax-withholding disposition is not an open-market sale, but a standard mechanism to cover required taxes on equity compensation.

What are the key details of the CEO’s restricted stock unit grant at Avalo Therapeutics (AVTX)?

On August 13, 2024, the CEO was granted 194,600 restricted stock units, vesting in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027. Each unit converts into one share of Avalo Therapeutics common stock, subject to his continued service.

Does the Avalo Therapeutics (AVTX) Form 4 show an open-market purchase or sale by the CEO?

The Form 4 does not show any open-market purchases or sales. It records an exercise of 64,866 restricted stock units into common shares and a tax-withholding disposition of 21,892 shares, which is a compensation and tax event rather than a discretionary market trade by the CEO.